Compare GDRX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | CERT |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | 1576 |
| Industry | Retail: Computer Software & Peripheral Equipment | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.9M | 860.9M |
| IPO Year | 2020 | 2020 |
| Metric | GDRX | CERT |
|---|---|---|
| Price | $2.04 | $5.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $3.86 | ★ $12.22 |
| AVG Volume (30 Days) | 1.8M | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 87.50 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $796,853,000.00 | $418,838,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | $5.38 | $5.40 |
| P/E Ratio | $22.78 | ★ N/A |
| Revenue Growth | 0.57 | ★ 8.75 |
| 52 Week Low | $1.77 | $5.24 |
| 52 Week High | $5.61 | $15.38 |
| Indicator | GDRX | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 24.20 |
| Support Level | $1.77 | N/A |
| Resistance Level | $2.47 | $11.62 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 37.50 | 11.18 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.